Gabapentin
Druggabapentin usage as adjunctive treatment for pain control
NCT Number: NCT02490345
The specific aims of this research study are to use 600 mg gabapentin as an adjunctive treatment for acute postoperative pain control in order to reduce postoperative opiate consumption and improve postoperative pain control.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 1
Eskenazi Health, Indianapolis, Indiana, United States
After consent has been obtained for the study and the cesarean has been completed, when the participant is in the recovery room, she will take the first pill of the study drug. This will occur approximately 30-60 minutes after the cesarean is completed. The time of first dose will be noted on the data capture form. The following will then occur:
An Edinburgh Depression Scale will also be administered upon consent, at 48 hours, and again at one week after delivery. If the scores meet the specified criteria, the provider will by notified or if the subject has already been discharged from the hospital, she will be given contact information for follow up care.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
gabapentin usage as adjunctive treatment for pain control
Identical placebo
Time frame: 48 hours after cesarean delivery
Time frame: one week after cesarean delivery
Time frame: one week after cesarean delivery
Time frame: one week after cesarean delivery
Indiana University
Other
Effect of Gabapentin on Postoperative Pain Control After a Cesarean Section
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06020391
Drug Usage
Oslo, Norway
View Trial DetailsNCT03368456
Acquired Immunodeficiency Syndrome, Adolescent Behavior
Ypsilanti, Michigan, United States
View Trial DetailsNCT03330782
Drug Usage, Neurologic Manifestations
Suwon, Gyeonggi-do, South Korea
View Trial DetailsNCT02379455
Drug Usage
Oslo, Norway
View Trial Details